Pakistan Drug Prices Set To Rise

20 October 1997

Prices of both imported and locally-produced pharmaceutical products inPakistan are to increase 10%-12%, following the latest devaluation of the rupee by 8.7%, drug industry sources in the capital, Karachi, have said. The increase will be the fifth in the last 21 months. The last rise was in November last year. Local commentators say that even the 4% relief on the prices of medicines which the government passed on to consumers in mid-August last year will be wiped out with the latest hike.

Only last week, Prime Minister Nawaz Sharif had assured a meeting in Lahore that the prices of a number of drugs in general use would be reduced from October 25 and, while this may be the policy, drug industry sources say it will be obliterated. The finance director of Eli Lilly Pakistan (Pvt) Ltd, Farrukh Faiyaz, said that the prices of imported medicines would go up by 10%-11%. A member of the Pakistan Pharmaceutical Manufacturers Association and managing director of Lisko Pakistan (Pvt) Ltd, Nazar Talib, said there would be an increase of some 11%-12% in the price of locally-made drugs. He added that local producers would incur an additional 3%-4% in duties for raw materials and packaging.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight